Thomas Matthew Habermann, MD

  • 20767 Citations
  • 76 Scopus h-Index
1978 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Thomas Matthew Habermann is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 27 Similar Profiles
Lymphoma, Large B-Cell, Diffuse Medicine & Life Sciences
Non-Hodgkin's Lymphoma Medicine & Life Sciences
Lymphoma Medicine & Life Sciences
Follicular Lymphoma Medicine & Life Sciences
Survival Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
B-Cell Lymphoma Medicine & Life Sciences
Hodgkin Disease Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1978 2017

Lymphoma Specialized Program of Research Excellence

Macon, W. R., Dogan, A. M., Ansell, S. M., Gupta, M. D., Witzig, T. E., Cerhan, J. R., Habermann, T. M., Ratliff, T. L., Link, B. K., Ratliff, T. L., Juweid, M., Ballas, Z., Link, B. K., Ratliff, T., Geyer, S. M., Weiner, G., Lentz, S., Hohl, R., Smith, B. J., Kaufmann, S. H., Feldman, A. L. & Witzig, T. E.

National Institutes of Health

9/11/026/30/17

Project: Research project

Lymphoma
Non-Hodgkin's Lymphoma
Molecular Epidemiology
B-Lymphocytes
B-Cell Lymphoma

EASTERN COOPERATIVE ONCOLOGY GROUP

Habermann, T. M., Hahn, R. & Edmonson, J.

National Institutes of Health

6/1/784/30/16

Project: Research project

Antineoplastic Protocols
Organized Financing
Neoplasms
Research
Clinical Protocols

Research Output 1983 2019

Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma

Wang, Y., Wenzl, K., Manske, M. K., Asmann, Y., Sarangi, V., Greipp, P. T., Krull, J. E., Hartert, K., He, R., Feldman, A. L., Maurer, M. J., Slager, S. L., Nowakowski, G. S., Habermann, T. M., Witzig, T. E., Link, B. K., Ansell, S. M., Cerhan, J. R. & Novak, A. J., Sep 1 2019, In : Blood cancer journal. 9, 9, 73.

Research output: Contribution to journalArticle

Open Access
Lymphoma, Large B-Cell, Diffuse
B-Cell Lymphoma
Immunotherapy
Lymphoma
Hodgkin Disease
3 Citations (Scopus)

B-cell lymphomas, version 3.2019: Featured updates to the NCCN Guidelines

Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Bartlett, N. L., Caimi, P. F., Chang, J. E., Chavez, J. C., Christian, B., Fayad, L. E., Glenn, M. J., Habermann, T. M., Harris, N. L., Hernandez-Ilizaliturri, F., Kaminski, M. S., Kelsey, C. R., Khan, N., Krivacic, S., LaCasce, A. S., Mehta, A. & 11 others, Nademanee, A., Rabinovitch, R., Reddy, N., Reid, E., Roberts, K. B., Smith, S. D., Snyder, E. D., Swinnen, L. J., VoseA, J. M., Dwyer, M. A. & Sundar, H., Jan 1 2019, In : JNCCN Journal of the National Comprehensive Cancer Network. 17, 6, p. 650-661 12 p.

Research output: Contribution to journalArticle

Open Access
Follicular Lymphoma
Lymphoma, Large B-Cell, Diffuse
B-Cell Lymphoma
Guidelines
Phosphatidylinositol 3-Kinase

Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era

Taparra, K., Liu, H., Polley, M. Y., Ristow, K., Habermann, T. M. & Ansell, S. M., Jan 1 2019, (Accepted/In press) In : Leukemia and Lymphoma.

Research output: Contribution to journalArticle

Bleomycin
Hodgkin Disease
Lung
Therapeutics
indium-bleomycin
11 Citations (Scopus)

Cause of death in follicular lymphoma in the first decade of the rituximab era: A pooled analysis of French and US cohorts

Sarkozy, C., Maurer, M. J., Link, B. K., Ghesquieres, H., Nicolas, E., Thompson, C. A., Traverse-Glehen, A., Feldman, A. L., Allmer, C., Slager, S. L., Ansell, S. M., Habermann, T. M., Bachy, E., Cerhan, J. R. & Salles, G., Jan 10 2019, In : Journal of Clinical Oncology. 37, 2, p. 144-152 9 p.

Research output: Contribution to journalArticle

Follicular Lymphoma
Cause of Death
Lymphoma
Disease-Free Survival
Rituximab
Follicular Lymphoma
Spleen
Bone and Bones
Survival
Disease-Free Survival